Preclinical data suggest TAAR1 agonists may be uniquely positioned to target the presynaptic mechanisms underlying dopamine synthesis capacity dysfunction in psychosis and modulate glutamatergic circuit alterations associated with core symptoms of schizophrenia. This evidence concerns the gene TAAR1 and schizophrenia.